Add Yahoo as a preferred source to see more of our stories on Google. Around 125 million people worldwide have psoriasis, the skin condition that causes flaky patches on the surface to form as scales.

Finding a cream that actually helps with psoriasis can make a real difference. Whether your skin is inflamed, sensitive, or just uncomfortable, the right skincare product can calm irritation and leave ...

Select independently determines what we cover and recommend. When you buy through our links, we may earn a commission. Learn more. From acne to sunburns, your skin is vulnerable to a range of ...

Findings showed that 88.5% of patients achieved target lesion Physician Global Assessment success at week 12. Tapinarof cream was found to be an effective treatment for plaque psoriasis of the head ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a ...

I've had scalp psoriasis for a few years now and I'm happy to say I have it mostly under control. I use a prescription shampoo from the dermatologist a few times a month and an over-the-counter (OTC) ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...

HUNTINGTON BEACH, Calif. — The US Food and Drug Administration (FDA) approvals of tapinarof 1% cream and roflumilast 0.3% cream as treatment options for patients with plaque psoriasis came more than 1 ...

- 88.5% of adult patients achieved a target lesion Physician Global Assessment (tPGA) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at Week 12 (tPGA Success), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 82.8% of patients treated with Vtama achieved the ...